Evaluating Treatment Response of Chronic Myeloid Leukemia: Emerging Science and Technology.

Evaluating Treatment Response of Chronic Myeloid Leukemia: Emerging Science and Technology.
Curr Cancer Drug Targets. 2013 Jul 30;
Authors: Garuti A, Cagnetta A, Marani C, Miglino M, Cea M, Rocco I, Palermo C, Fugazza G, Cirmena G, Colombo N, Grasso R, Nencioni A, Gobbi M, Patrone F
Abstract
Chronic myeloid leukemia (CML) is a hematological disease that represents 20% of all adult leukemias. The biologic and clinical advances obtained in CML are the most successful examples of translational medicine, in which identification of the fusion oncogene BCR-ABL has allowed the discovery of small molecule inhibitors of its tyrosine kinase activity which, in turn, have literally revolutionized the treatment of such malignancy. However, large part of a successful clinical management of CML relies on appropriate diagnosis, molecular monitoring and identification of mutations potentially leading to drug resistance. Notably the recent availability of refined laboratory equipments represented by the Next Generation Sequencing (NGS) technologies and genomic analyses has further contributed to reach the last step towards the cure of this tumor. These issues are discussed here together with an overview on how patients treated with tyrosine kinase inhibitors should be monitored.
PMID: 23906053 [PubMed - as supplied by publisher]

Source: Current Cancer Drug Targets - July 30, 2013 Category: Cancer & Oncology Authors: Garuti A, Cagnetta A, Marani C, Miglino M, Cea M, Rocco I, Palermo C, Fugazza G, Cirmena G, Colombo N, Grasso R, Nencioni A, Gobbi M, Patrone F Tags: Curr Cancer Drug Targets Source Type: research